{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:13:02Z","timestamp":1780625582836,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["18H02684"],"award-info":[{"award-number":["18H02684"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17H06329"],"award-info":[{"award-number":["17H06329"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>RAS signaling is a promising target for colorectal cancer (CRC) therapy, and a variety of selective inhibitors have been developed. However, their use has often failed to demonstrate a significant benefit in CRC patients. Here, we used patient-derived organoids (PDOs) derived from a familial adenomatous polyposis (FAP) patient to analyze the response to chemotherapeutic agents targeting EGFR, BRAF and MEK. We found that PDOs carrying KRAS mutations were resistant to MEK inhibition, while those harboring the BRAF class 3 mutation were hypersensitive. We used a systematic approach to examine the phosphorylation of RAS effectors using reverse-phase protein array (RPPA) and found increased phosphorylation of MEK induced by binimetinib. A high basal level of ERK phosphorylation and its rebound activation after MEK inhibition were detected in KRAS-mutant PDOs. Notably, the phosphorylation of EGFR and AKT was more closely correlated with that of MEK than that of ERK. Transcriptome analysis identified MYC-mediated transcription and IFN signaling as significantly correlated gene sets in MEK inhibition. Our experiments demonstrated that RPPA analysis of PDOs, in combination with the genome and transcriptome, is a useful preclinical research platform to understand RAS signaling and provides clues for the development of chemotherapeutic strategies.<\/jats:p>","DOI":"10.1038\/s41598-020-74530-x","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T10:04:27Z","timestamp":1602756267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient"],"prefix":"10.1038","volume":"10","author":[{"given":"Hiroki","family":"Osumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Muroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Sakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Natsume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kusama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ooki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Koshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"74530_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/s1470-2045(10)70130-3","volume":"11","author":"W De Roock","year":"2010","unstructured":"De Roock, W. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753\u2013762. https:\/\/doi.org\/10.1016\/s1470-2045(10)70130-3 (2010).","journal-title":"Lancet Oncol."},{"key":"74530_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949\u2013954. https:\/\/doi.org\/10.1038\/nature00766 (2002).","journal-title":"Nature"},{"key":"74530_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/sj.bjc.6605177","volume":"101","author":"F Loupakis","year":"2009","unstructured":"Loupakis, F. et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer 101, 715\u2013721. https:\/\/doi.org\/10.1038\/sj.bjc.6605177 (2009).","journal-title":"Br. J. Cancer"},{"key":"74530_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/emboj.2010.7","volume":"29","author":"M Drosten","year":"2010","unstructured":"Drosten, M. et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 29, 1091\u20131104. https:\/\/doi.org\/10.1038\/emboj.2010.7 (2010).","journal-title":"EMBO J."},{"key":"74530_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ccell.2019.12.009","volume":"37","author":"F McCormick","year":"2020","unstructured":"McCormick, F. Sticking it to KRAS: covalent inhibitors enter the clinic. Cancer Cell 37, 3\u20134. https:\/\/doi.org\/10.1016\/j.ccell.2019.12.009 (2020).","journal-title":"Cancer Cell"},{"key":"74530_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nchembio.1560","volume":"10","author":"J Spiegel","year":"2014","unstructured":"Spiegel, J., Cromm, P. M., Zimmermann, G., Grossmann, T. N. & Waldmann, H. Small-molecule modulation of Ras signaling. Nat. Chem. Biol. 10, 613\u2013622. https:\/\/doi.org\/10.1038\/nchembio.1560 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"74530_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nrd.2016.29","volume":"15","author":"DE Scott","year":"2016","unstructured":"Scott, D. E., Bayly, A. R., Abell, C. & Skidmore, J. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat. Rev. Drug Discov. 15, 533\u2013550. https:\/\/doi.org\/10.1038\/nrd.2016.29 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"74530_CR8","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard, D. et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 17, 984\u2013993. https:\/\/doi.org\/10.1016\/S1470-2045(16)30146-2 (2016).","journal-title":"Lancet Oncol."},{"key":"74530_CR9","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 381, 1632\u20131643. https:\/\/doi.org\/10.1056\/NEJMoa1908075 (2019).","journal-title":"N. Engl. J. Med."},{"key":"74530_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.Cd-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran, R. B. et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov. 8, 428\u2013443. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1226 (2018).","journal-title":"Cancer Discov."},{"key":"74530_CR11","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible?. Nat. Rev. Drug Discov. 13, 828\u2013851. https:\/\/doi.org\/10.1038\/nrd4389 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"74530_CR12","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.3392","volume":"19","author":"P Lito","year":"2013","unstructured":"Lito, P., Rosen, N. & Solit, D. B. Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 19, 1401\u20131409. https:\/\/doi.org\/10.1038\/nm.3392 (2013).","journal-title":"Nat. Med."},{"key":"74530_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aay6013","author":"CA Stalnecker","year":"2020","unstructured":"Stalnecker, C. A. & Der, C. J. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers. Sci. Signal. https:\/\/doi.org\/10.1126\/scisignal.aay6013 (2020).","journal-title":"Sci. Signal."},{"key":"74530_CR14","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1172\/JCI57909","volume":"121","author":"H Ebi","year":"2011","unstructured":"Ebi, H. et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J. Clin. Investig. 121, 4311\u20134321. https:\/\/doi.org\/10.1172\/JCI57909 (2011).","journal-title":"J. Clin. Investig."},{"key":"74530_CR15","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke, A. B. et al. MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 72, 3228\u20133237. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3747 (2012).","journal-title":"Cancer Res."},{"key":"74530_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933\u2013945. https:\/\/doi.org\/10.1016\/j.cell.2015.03.053 (2015).","journal-title":"Cell"},{"key":"74530_CR17","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920\u2013926. https:\/\/doi.org\/10.1126\/science.aao2774 (2018).","journal-title":"Science"},{"key":"74530_CR18","first-page":"2399","volume":"8","author":"S Ichii","year":"1993","unstructured":"Ichii, S. et al. Detailed analysis of genetic alterations in colorectal tumors from patients with and without familial adenomatous polyposis (FAP). Oncogene 8, 2399\u20132405 (1993).","journal-title":"Oncogene"},{"key":"74530_CR19","first-page":"1875","volume":"10","author":"S Gallinger","year":"1995","unstructured":"Gallinger, S. et al. Somatic APC and K-ras codon 12 mutations in periampullary adenomas and carcinomas from familial adenomatous polyposis patients. Oncogene 10, 1875\u20131878 (1995).","journal-title":"Oncogene"},{"key":"74530_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/bfgp\/1.3.305","volume":"1","author":"L Charboneau","year":"2002","unstructured":"Charboneau, L. et al. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief. Funct. Genom. Proteomics 1, 305\u2013315. https:\/\/doi.org\/10.1093\/bfgp\/1.3.305 (2002).","journal-title":"Brief. Funct. Genom. Proteomics"},{"key":"74530_CR21","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40291-014-0122-3","volume":"18","author":"RI Gallagher","year":"2014","unstructured":"Gallagher, R. I. & Espina, V. Reverse phase protein arrays: mapping the path towards personalized medicine. Mol. Diagnosis Ther. 18, 619\u2013630. https:\/\/doi.org\/10.1007\/s40291-014-0122-3 (2014).","journal-title":"Mol. Diagnosis Ther."},{"key":"74530_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1053\/j.seminoncol.2016.06.005","volume":"43","author":"Y Lu","year":"2016","unstructured":"Lu, Y. et al. Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin. Oncol. 43, 476\u2013483. https:\/\/doi.org\/10.1053\/j.seminoncol.2016.06.005 (2016).","journal-title":"Semin. Oncol."},{"key":"74530_CR23","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/cas.13964","volume":"110","author":"M Sakahara","year":"2019","unstructured":"Sakahara, M. et al. IFN\/STAT signaling controls tumorigenesis and the drug response in colorectal cancer. Cancer Sci. 110, 1293\u20131305. https:\/\/doi.org\/10.1111\/cas.13964 (2019).","journal-title":"Cancer Sci."},{"key":"74530_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.critrevonc.2006.07.004","volume":"61","author":"MH Nieuwenhuis","year":"2007","unstructured":"Nieuwenhuis, M. H. & Vasen, H. F. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit. Rev. Oncol. Hematol. 61, 153\u2013161. https:\/\/doi.org\/10.1016\/j.critrevonc.2006.07.004 (2007).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"74530_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","volume":"548","author":"Z Yao","year":"2017","unstructured":"Yao, Z. et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548, 234\u2013238. https:\/\/doi.org\/10.1038\/nature23291 (2017).","journal-title":"Nature"},{"key":"74530_CR26","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.18.02459","volume":"37","author":"E Van Cutsem","year":"2019","unstructured":"Van Cutsem, E. et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. J. Clin. Oncol. 37, 1460\u20131469. https:\/\/doi.org\/10.1200\/JCO.18.02459 (2019).","journal-title":"J. Clin. Oncol."},{"key":"74530_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427\u2013430. https:\/\/doi.org\/10.1038\/nature08902 (2010).","journal-title":"Nature"},{"key":"74530_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","volume":"464","author":"G Hatzivassiliou","year":"2010","unstructured":"Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431\u2013435. https:\/\/doi.org\/10.1038\/nature08833 (2010).","journal-title":"Nature"},{"key":"74530_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","volume":"140","author":"SJ Heidorn","year":"2010","unstructured":"Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209\u2013221. https:\/\/doi.org\/10.1016\/j.cell.2009.12.040 (2010).","journal-title":"Cell"},{"key":"74530_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13073-016-0366-0","volume":"8","author":"FS Dela Cruz","year":"2016","unstructured":"Dela Cruz, F. S. et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 8, 116. https:\/\/doi.org\/10.1186\/s13073-016-0366-0 (2016).","journal-title":"Genome Med."},{"key":"74530_CR31","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1210093 (2012).","journal-title":"N. Engl. J. Med."},{"key":"74530_CR32","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1158\/1078-0432.CCR-14-0341","volume":"20","author":"L Zimmer","year":"2014","unstructured":"Zimmer, L. et al. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clin. Cancer Res. 20, 4251\u20134261. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0341 (2014).","journal-title":"Clin. Cancer Res."},{"key":"74530_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/bjc.2017.10","volume":"116","author":"JC Bendell","year":"2017","unstructured":"Bendell, J. C. et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1\/2 inhibitor. Br. J. Cancer 116, 575\u2013583. https:\/\/doi.org\/10.1038\/bjc.2017.10 (2017).","journal-title":"Br. J. Cancer"},{"key":"74530_CR34","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","volume":"25","author":"P Lito","year":"2014","unstructured":"Lito, P. et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 25, 697\u2013710. https:\/\/doi.org\/10.1016\/j.ccr.2014.03.011 (2014).","journal-title":"Cancer Cell"},{"key":"74530_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nature18600","volume":"534","author":"E Manchado","year":"2016","unstructured":"Manchado, E. et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534, 647\u2013651. https:\/\/doi.org\/10.1038\/nature18600 (2016).","journal-title":"Nature"},{"key":"74530_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.celrep.2014.02.045","volume":"7","author":"C Sun","year":"2014","unstructured":"Sun, C. et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 7, 86\u201393. https:\/\/doi.org\/10.1016\/j.celrep.2014.02.045 (2014).","journal-title":"Cell Rep."},{"key":"74530_CR37","doi-asserted-by":"publisher","first-page":"10463","DOI":"10.1038\/s41598-017-10478-9","volume":"7","author":"Y Abe","year":"2017","unstructured":"Abe, Y. et al. Deep phospho- and phosphotyrosine proteomics identified active kinases and phosphorylation networks in colorectal cancer cell lines resistant to cetuximab. Sci. Rep. 7, 10463. https:\/\/doi.org\/10.1038\/s41598-017-10478-9 (2017).","journal-title":"Sci. Rep."},{"key":"74530_CR38","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/1878-0261.12698","volume":"14","author":"X Yuan","year":"2020","unstructured":"Yuan, X. et al. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors. Mol. Oncol. 14, 1833\u20131849. https:\/\/doi.org\/10.1002\/1878-0261.12698 (2020).","journal-title":"Mol. Oncol."},{"key":"74530_CR39","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc4000","volume":"15","author":"CJ Caunt","year":"2015","unstructured":"Caunt, C. J., Sale, M. J., Smith, P. D. & Cook, S. J. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat. Rev. Cancer 15, 577\u2013592. https:\/\/doi.org\/10.1038\/nrc4000 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"74530_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13964","author":"M Sakahara","year":"2019","unstructured":"Sakahara, M. et al. IFN\/STAT signaling controls tumorigenesis and the drug response in colorectal cancer. Cancer Sci. https:\/\/doi.org\/10.1111\/cas.13964 (2019).","journal-title":"Cancer Sci."},{"key":"74530_CR41","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/s41388-018-0554-z","volume":"38","author":"S Wagner","year":"2019","unstructured":"Wagner, S. et al. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Oncogene 38, 1717\u20131733. https:\/\/doi.org\/10.1038\/s41388-018-0554-z (2019).","journal-title":"Oncogene"},{"key":"74530_CR42","first-page":"3595","volume":"61","author":"CK Weber","year":"2001","unstructured":"Weber, C. K., Slupsky, J. R., Kalmes, H. A. & Rapp, U. R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595\u20133598 (2001).","journal-title":"Cancer Res."},{"key":"74530_CR43","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/s0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855\u2013867. https:\/\/doi.org\/10.1016\/s0092-8674(04)00215-6 (2004).","journal-title":"Cell"},{"key":"74530_CR44","doi-asserted-by":"publisher","first-page":"7089","DOI":"10.1158\/1078-0432.CCR-19-2004","volume":"25","author":"R Yaeger","year":"2019","unstructured":"Yaeger, R. et al. Response to anti-EGFR therapy in patients with BRAF non-V600-mutant metastatic colorectal cancer. Clin. Cancer Res. 25, 7089\u20137097. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2004 (2019).","journal-title":"Clin. Cancer Res."},{"key":"74530_CR45","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1038\/bjc.2014.100","volume":"110","author":"K Malinowsky","year":"2014","unstructured":"Malinowsky, K. et al. Activation of the PI3K\/AKT pathway correlates with prognosis in stage II colon cancer. Br. J. Cancer 110, 2081\u20132089. https:\/\/doi.org\/10.1038\/bjc.2014.100 (2014).","journal-title":"Br. J. Cancer"},{"key":"74530_CR46","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00432-013-1437-x","volume":"139","author":"C Wei","year":"2013","unstructured":"Wei, C., Chen, J., Pande, M., Lynch, P. M. & Frazier, M. L. A pilot study comparing protein expression in different segments of the normal colon and rectum and in normal colon versus adenoma in patients with Lynch syndrome. J. Cancer Res. Clin. Oncol. 139, 1241\u20131250. https:\/\/doi.org\/10.1007\/s00432-013-1437-x (2013).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"74530_CR47","doi-asserted-by":"publisher","first-page":"e1900091","DOI":"10.1002\/prca.201900091","volume":"14","author":"M Suzuki","year":"2020","unstructured":"Suzuki, M. et al. Utility of a reverse phase protein array to evaluate multiple biomarkers in diffuse large B-cell lymphoma. Proteomics Clin. Appl. 14, e1900091. https:\/\/doi.org\/10.1002\/prca.201900091 (2020).","journal-title":"Proteomics Clin. Appl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74530-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74530-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74530-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T21:57:11Z","timestamp":1670363831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74530-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["74530"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-74530-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"19 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17455"}}